| Year |
Citation |
Score |
| 2020 |
Fang B, Izumi V, Rix LLR, Welsh E, Pike I, Reuther GW, Haura EB, Rix U, Koomen JM. Lowering Sample Requirements to Study Tyrosine Kinase Signaling using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. e2000116. PMID 32865326 DOI: 10.1002/Pmic.202000116 |
0.302 |
|
| 2019 |
Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, et al. Proteogenomic landscape of squamous cell lung cancer. Nature Communications. 10: 3578. PMID 31395880 DOI: 10.1038/S41467-019-11452-X |
0.41 |
|
| 2019 |
Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology. PMID 31257184 DOI: 10.1016/J.Chembiol.2019.06.003 |
0.357 |
|
| 2019 |
Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 10: 810-824. PMID 30783512 DOI: 10.18632/Oncotarget.26574 |
0.411 |
|
| 2019 |
Koomen DC, Meads MB, Magaletti DM, Guingab JD, Oliveira PS, Fang B, Izumi V, Renatino-Canevarolo R, Sudalagunta PR, Silva M, Alugubelli R, De Avilla G, Tungeskiv A, Welsh EA, Meke LE, et al. Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma Blood. 134: 5534-5534. DOI: 10.1182/Blood-2019-132001 |
0.323 |
|
| 2019 |
Burger KL, Meads MB, Berglund A, Oliveira PS, Distler A, Sudalagunta PR, Jacobson T, Teer J, Welsh EA, Dai H, Koomen JM, Raghunandan Reddy A, De Avila G, Tungesvik A, Roush W, et al. A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma Blood. 134: 5537-5537. DOI: 10.1182/Blood-2019-130830 |
0.343 |
|
| 2019 |
Renatino-Canevarolo R, Sudalagunta PR, Coelho Siqueira Silva MD, Meads MB, Tungesvik A, De Avila G, Raghunandan Reddy A, Nong M, Teer J, Welsh EA, Lwin T, Kulkarni A, Dai H, Dalton WS, Shain KH, et al. Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance Blood. 134: 5544-5544. DOI: 10.1182/Blood-2019-128442 |
0.317 |
|
| 2019 |
Majumder A, Zhang G, Adhikari E, Fang B, Welsh EA, Koomen JM, Haura EB. Abstract 4543: Proteomic characterization of AXL kinase inhibitors and signaling pathways Cancer Research. 79: 4543-4543. DOI: 10.1158/1538-7445.Am2019-4543 |
0.368 |
|
| 2019 |
Rix LLR, Sumi NJ, Bryant AT, Li X, Welsh EA, Fang B, Kuenzi BM, Antonia SJ, Marusyk A, Lovly CM, Koomen JM, Haura EB, Rix U. Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C110 |
0.403 |
|
| 2019 |
Palve V, Knezevic C, Luo Y, Li X, Novakova S, Welsh E, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Lawrence HR, Rix U. Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B021 |
0.366 |
|
| 2018 |
Ahmed KA, Scott JG, Arrington JA, Naghavi AO, Grass GD, Perez BA, Caudell JJ, Berglund AE, Welsh EA, Eschrich SA, Dilling TJ, Torres-Roca JF. Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29733909 DOI: 10.1016/J.Jtho.2018.04.027 |
0.328 |
|
| 2018 |
Cress WD, Gimbrone NT, Sarcar B, Gordian E, Rivera JI, Lopez C, Teer JK, Welsh EA, Chiappori AA, Schabath MB, Reuther GW, Santiago-Cardona PG. Abstract PR03: Somatic mutations and ancestry markers in Hispanic lung cancer patients Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-Pr03 |
0.365 |
|
| 2018 |
Welsh EA, Stewart PA, Chambers MC, Zhang G, Fang B, Eschrich SA, Koomen JM, Haura EB. Abstract 2708: Imputation-free analysis of high throughput TMT proteomics of 116 lung squamous samples Cancer Research. 78: 2708-2708. DOI: 10.1158/1538-7445.Am2018-2708 |
0.352 |
|
| 2018 |
Zhang G, Ross K, Fang B, Zhou J, Stewart PA, Adhikari E, Welsh EA, Wang X, Koomen JM, Wu CH, Haura EB. Abstract 1308: Post translational crosstalk networks identify strategies to overcome EMT-mediated resistance to EGFR inhibitors Cancer Research. 78: 1308-1308. DOI: 10.1158/1538-7445.Am2018-1308 |
0.357 |
|
| 2017 |
Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, Zhou JM, Boulware DC, Kim J, Haura EB, Morse DL. Cell-surface marker discovery for lung cancer. Oncotarget. 8: 113373-113402. PMID 29371917 DOI: 10.18632/Oncotarget.23009 |
0.389 |
|
| 2017 |
Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiaporri AA, Schabath MB, Reuther GW, Dutil J, Garcia M, Ventosilla-Villanueva R, Vera-Valdivia L, et al. Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28911955 DOI: 10.1016/J.Jtho.2017.08.019 |
0.351 |
|
| 2017 |
Stewart PA, Fang B, Slebos RJ, Zhang G, Borne AL, Fellows K, Teer JK, Chen YA, Welsh E, Eschrich SA, Haura EB, Koomen JM. Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. Proteomics. PMID 28195392 DOI: 10.1002/Pmic.201600300 |
0.309 |
|
| 2017 |
Sumi NJ, Fang B, Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC Cancer Research. 77: 221-221. DOI: 10.1158/1538-7445.Am2017-221 |
0.392 |
|
| 2017 |
Slebos RJC, Stewart PA, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Pettersson F, Berglund AE, Zhang G, Fang B, Izumi V, Yoder SJ, Fellows KM, Chen YA, et al. Abstract 206: Proteogenomic classifications and outcome in squamous cell carcinoma of the lung Cancer Research. 77: 206-206. DOI: 10.1158/1538-7445.Am2017-206 |
0.305 |
|
| 2017 |
Stewart PA, Slebos RJ, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Pettersson F, Berglund A, Zhang G, Fang B, Izumi V, Yoder S, Fellows K, Chen A, et al. Abstract 205: Underlying mechanisms of genome-proteome discordance in squamous cell lung cancer Cancer Research. 77: 205-205. DOI: 10.1158/1538-7445.Am2017-205 |
0.376 |
|
| 2017 |
Pettersson F, Stewart PA, Slebos RJ, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Zhang G, Fang B, Izumi V, Yoder S, Fellows K, Chen YA, Teer JK, et al. Abstract 1565: OnPLS-based integrative proteogenomics analysis of lung squamous cell cancer Cancer Research. 77: 1565-1565. DOI: 10.1158/1538-7445.Am2017-1565 |
0.364 |
|
| 2016 |
Kim JY, Stewart PA, Borne AL, Fang B, Welsh EA, Chen YA, Eschrich SA, Koomen JM, Haura EB. Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. Proteomes. 4: 16. PMID 28154798 DOI: 10.3390/Proteomes4020016 |
0.361 |
|
| 2016 |
Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, et al. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. PMID 27756884 DOI: 10.18632/Oncotarget.12672 |
0.333 |
|
| 2016 |
Ahmed KA, Berglund AE, Welsh EA, Naghavi AO, Perez BA, Dilling TJ, Eschrich SA, Torres-Roca JF. Differences in the Radiosensitivity Index (RSI) Between Lung Metastases Based Upon Primary Histology. International Journal of Radiation Oncology, Biology, Physics. 96: S68. PMID 27675988 DOI: 10.1016/J.Ijrobp.2016.06.173 |
0.317 |
|
| 2016 |
Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB. Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer. Molecular Cancer Research : McR. PMID 27422710 DOI: 10.1158/1541-7786.Mcr-15-0506 |
0.338 |
|
| 2016 |
Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD. A sensitive NanoString-based assay to score STK11 (LKB1) pathway disruption in lung adenocarcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26917230 DOI: 10.1016/J.Jtho.2016.02.009 |
0.378 |
|
| 2016 |
Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura E, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ. Abstract A22: An LKB1-CRTC1 circuit regulates glycosylated COX-2 and predicts drug response in lung cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A22 |
0.389 |
|
| 2016 |
Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, Cress WD, Wu J. Abstract 190: Mechanism ofCDKN3overexpression in cancer Cancer Research. 76: 190-190. DOI: 10.1158/1538-7445.Am2016-190 |
0.397 |
|
| 2016 |
McClung EC, Berglund A, Welsh E, Xiong Y, Robertson S, Boac B, Chon HS, Magliocco A, Marchion D. Exploring Associations Between Tumor Derived B-cell and T-cell Infiltration Gene Signatures and Clinicopathologic Features in Endometrioid Endometrial Carcinoma Gynecologic Oncology. 143: 198. DOI: 10.1016/J.Ygyno.2016.08.251 |
0.302 |
|
| 2015 |
Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, Cai J, Cress WD, Wu J. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. British Journal of Cancer. PMID 26554648 DOI: 10.1038/Bjc.2015.378 |
0.356 |
|
| 2015 |
Stewart PA, Parapatics K, Welsh EA, Müller AC, Cao H, Fang B, Koomen JM, Eschrich SA, Bennett KL, Haura EB. A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. Plos One. 10: e0142162. PMID 26539827 DOI: 10.1371/Journal.Pone.0142162 |
0.363 |
|
| 2015 |
Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ. Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer. Journal of the National Cancer Institute. 107: 358. PMID 25465874 DOI: 10.1093/Jnci/Dju358 |
0.35 |
|
| 2015 |
Dai H, Wenham RM, Kumar N, Mitchell M, Crim A, Welsh E, Berglund AE, Huntsman S, Cristescu R, Nebozhyn M, Loboda A, Sullivan D, Dalton WS. Prognostic and predictive signature discovery and validation in ovarian cancer utilizing the total-cancer-care (TCC) data warehouse. Journal of Clinical Oncology. 33: e22167-e22167. DOI: 10.1200/Jco.2015.33.15_Suppl.E22167 |
0.355 |
|
| 2015 |
Kim J, Welsh EA, Fang B, Kinose F, Koomen JM, Haura EB. Abstract 668: Phosphoproteomic characterization of selumetinib action in KRAS mutant lung cancer Cancer Research. 75: 668-668. DOI: 10.1158/1538-7445.Am2015-668 |
0.335 |
|
| 2015 |
Stewart PA, Li J, Fisher KJ, Dhungana S, Stewart D, Sumner S, Gardner E, Poirier J, Rudin CM, Welsh EA, Eschrich S, Chen A, Haura EB. Abstract 3752: Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer Cancer Research. 75: 3752-3752. DOI: 10.1158/1538-7445.Am2015-3752 |
0.37 |
|
| 2015 |
Martinez M, Fang B, Li J, Chen YA, Brantley S, Guan W, Kinose F, Welsh E, Eschrich SA, Haura EB, Koomen JM. Abstract 1817: Quantitative proteomics identifies unique signaling phenotypes in NSCLC Cancer Research. 75: 1817-1817. DOI: 10.1158/1538-7445.Am2015-1817 |
0.396 |
|
| 2014 |
Haake SM, Brooks SA, Welsh E, Berglund A, Fulp WJ, Chen D, Haura EB, Sexton WJ, Spiess PE, Pow-Sang J, Rathmell K, Fishman MN. Molecular subtypes of clear cell renal cell carcinoma: Impact of diabetes mellitus, metformin, and immunotherapy on patient outcomes. Journal of Clinical Oncology. 32: 4579-4579. DOI: 10.1200/Jco.2014.32.15_Suppl.4579 |
0.338 |
|
| 2014 |
Kim J, Fang B, Welsh EA, Kinose F, Li J, Eschrich SA, Koomen JM, Haura EB. Abstract A31: Activity-based protein profiling reveals adaptive response to pharmacological MEK inhibition in KRAS mutant non-small cell lung cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A31 |
0.396 |
|
| 2014 |
Kurtyka CA, Chen L, Schabath MB, Chen D, Brazelle W, Welsh EA, Berglund AE, Eschrich SA, Gray JE, Haura EB, Cress WD. Abstract 914: Development of a prognostic and predictive E2F signature in formalin-fixed, paraffin-embedded early-stage non-small cell lung cancer samples Cancer Research. 74: 914-914. DOI: 10.1158/1538-7445.Am2014-914 |
0.39 |
|
| 2014 |
Gordian E, Welsh E, Muñoz-Antonia T. Abstract 1050: Alvespimycin (17-DMAG) blocks TGFβ-induced EMT and migration in A549 lung cancer cells Cancer Research. 74: 1050-1050. DOI: 10.1158/1538-7445.Am2014-1050 |
0.374 |
|
| 2013 |
Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: 12414-9. PMID 23836654 DOI: 10.1073/Pnas.1220674110 |
0.4 |
|
| 2013 |
Kim J, Welsh EA, Fang B, Oguz U, Li J, Kinose F, Bronk C, Beg AA, Chen A, Eschrich S, Koomen J, Haura EB. Abstract 937: Dissection of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer cells. Cancer Research. 73: 937-937. DOI: 10.1158/1538-7445.Am2013-937 |
0.414 |
|
| 2013 |
Berglund AE, Welsh EA, Fenstermacher DA, Eschrich SA. Abstract 2905: Validation techniques for PCA-based gene expression signatures. Cancer Research. 73: 2905-2905. DOI: 10.1158/1538-7445.Am2013-2905 |
0.34 |
|
| 2013 |
Kurtyka CA, Chen D, Chen L, Brazelle W, Welsh EA, Berglund AE, Eschrich SA, Schabath MB, Haura EB, Cress WD. Abstract 2354: An E2F signature predicts benefit of adjuvant chemotherapy in early-stage non-small cell lung cancer. Cancer Research. 73: 2354-2354. DOI: 10.1158/1538-7445.Am2013-2354 |
0.378 |
|
| 2013 |
Kim J, Welsh EA, Fang B, Li J, Eschrich SA, Koomen J, Haura EB. Abstract A61: Characterization of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A61 |
0.405 |
|
| 2012 |
Haura EB, Yoshida T, Fang B, Stukalov A, Eschrich S, Welsh E, Colinge J, Koomen J, Superti-Furga G, Li J, Rix U, Zhang G, Kim J, Bennett K, Song L, et al. Abstract IA2: Network models in oncogene-addicted lung cancer Clinical Cancer Research. 18: IA2-IA2. DOI: 10.1158/1078-0432.12Aacriaslc-Ia2 |
0.371 |
|
| 2011 |
Stöckel J, Jacobs JM, Elvitigala TR, Liberton M, Welsh EA, Polpitiya AD, Gritsenko MA, Nicora CD, Koppenaal DW, Smith RD, Pakrasi HB. Diurnal rhythms result in significant changes in the cellular protein complement in the cyanobacterium Cyanothece 51142. Plos One. 6: e16680. PMID 21364985 DOI: 10.1371/Journal.Pone.0016680 |
0.317 |
|
| 2004 |
Berglund A, Head RD, Welsh EA, Marshall GR. ProVal: a protein-scoring function for the selection of native and near-native folds. Proteins. 54: 289-302. PMID 14696191 DOI: 10.1002/Prot.10523 |
0.45 |
|
| Show low-probability matches. |